PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia

Fang-Fang Huang1*, Li Zhang2*, Deng-Shu Wu1, Xiao-Yu Yuan1, Fang-Ping Chen1, Hui Zeng1*, Yan-Hui Yu1, Xie-Lan Zhao1

1 Department of Hematology, Xiang Ya Hospital, Central South University, Changsha, Hunan, China, 2 Department of Hematology, West China Hospital, Si Chuan University, Chengdu, Sichuan, China

Abstract
A small population of cancer stem cells named the “side population” (SP) has been demonstrated to be responsible for the persistence of many solid tumors. However, the role of the SP in leukemic pathogenesis remains controversial. The resistance of leukemic stem cells to targeted therapies, such as tyrosine kinase inhibitors (TKIs), results in therapeutic failure or refractory/relapsed disease in chronic myeloid leukemia (CML). The drug pump, ATP-binding cassette sub-family G member 2 (ABCG2), is well known as a specific marker of the SP and could be controlled by several pathways, including the PI3K/Akt pathway. Our data demonstrated that compared with wild-type K562 cells, the higher percentage of ABCG2+ cells corresponded to the higher SP fraction in K562/ABCG2 (ABCG2 overexpressing) and K562/IMR (resistance to imatinib) cells, which exhibited enhanced drug resistance along with downregulated phosphatase and tensin homologue deleted on chromosome -10 (PTEN) and activated phosphorylated-Akt (p-Akt). PTEN and p-Akt downregulation could be abrogated by both the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin. Moreover, in CML patients in the accelerated phase/blastic phase (AP/BP), increased SP phenotype along with ABCG2 expression was accompanied by the loss of PTEN protein and the up-regulation of p-Akt expression. These results suggested that the expression of ABCG2 and the SP may be regulated by PTEN through the PI3K/Akt pathway, which would be a potentially effective strategy for targeting CML stem cells.

Introduction
Chronic myeloid leukemia (CML) is a clonal bone marrow stem cell disorder that accounts for 7–20% of all leukemia cases and has an estimated incidence of 1–2 per 100,000 worldwide [1]. CML arises by a reciprocal translocation between the long arms of chromosome 9 and chromosome 22 in an early hematopoietic stem cell (HSC) to produce the Philadelphia chromosome [2,3,4]. Although tyrosine kinase inhibitors (TKI) such as imatinib mesylate, nilotinib and dasatinib have been proven to be highly effective in the treatment of CML [5,6,7], a considerable number of the patients unfortunately face relapse or are unable to obtain complete remission during TKI therapy [8,9,10]. The relative quiescence of CML stem cells or the overexpression of drug transporters are currently considered the main factors contributing to impaired effectiveness for CML treatments [11,12,13].

The side population (SP), which can be identified and sorted by the efflux of Hoechst 33342, expresses stem cell properties, such as pluripotency and differentiation ability. ATP-binding cassette sub-family G member 2 (ABCG2), which is also known as breast cancer resistance protein (BCRP), is defined as a specific marker of the SP in a variety types of stem cells based on its ability to efflux Hoechst 33342 [14,15,16]. Previous results from adult acute myeloid leukemia demonstrated that SP cells may represent candidate leukemia stem cells. However, the role of ABCG2 expression and the SP phenotype in the mechanism of resistance to TKI in CML stem cells remains unclear [17]. Interestingly, the tumor suppressor gene phosphatase and tensin homologue deleted on chromosome-10 (PTEN), which is often deleted or inactivated in many solid tumor types [18,19,20], has also been shown to be down-regulated by BCR-ABL in CML stem cells, and its deletion can accelerate CML development through the regulation of its downstream target, Akt1 [21]. Moreover, PTEN was described as regulating the SP but not the expression of ABCG2 in glioma tumor stem-like cells through the PI3K/Akt pathway [22]. We speculate that the crosstalk between ABCG2 and PTEN in CML mediates therapeutic resistance and disease progression in CML cells, particularly within the SP compartment. As such, we
analyzed data from both CML cell lines and clinical samples from CML patients (Tab. 1).

Materials and Methods

Cell lines and culture condition
K562 cells were purchased from a cell resource center (Xiang-Ya Medical College, Central South University, Hunan, China). K562/IMR and K562/AO2 cells were kindly obtained from the Institute of Hematology and Blood Diseases Hospital (Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China) and the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China), respectively. Cell lines were routinely maintained in RPMI-1640 medium (GIBCO, NY, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, MA, USA) and 1% penicillin/streptomycin (Sigma, MO, USA) in the humidified atmosphere of a 5% CO2 incubator at 37°C. The PI3K inhibitor LY294002 (Invitrogen, Carlsbad, CA, USA) and the mTOR inhibitor rapamycin (Invitrogen, Carlsbad, CA, USA) were added to leukemia cells for 72 hours prior to mitoxantrone in some experiments.

Patient characteristics
From 2010 to 2012, bone marrow samples were obtained from 96 CML patients and 10 healthy candidate donors for hematopoietic stem cell transplantation as controls enrolled at the Xiang-Ya Hospital of Central South University, Hunan, China (Table 1). All patients and donors gave informed consent. The protocol was approved by the Medical Ethic committee of Xiangya Hospital, Central South University. Participants provided their written informed consent to participate in this study. The diagnosis and classification of the leukemia were based on 2008 World Health Organization’s criteria. Mononuclear cells (MNCs) were obtained by density centrifugation over Ficoll-Paque (Sigma, MO, USA) and stored at −80°C.

Cytotoxicity assay
Cells were cultured with various concentrations of the indicated agents. Cell viability was determined by a CCK8 assay (Nanjing Key Gen Biotechnology, Nan Jing, China). Briefly, cells were seeded in 96-well culture plates (8×10³ per well) in 100 µl media for 12 h. Subsequently, different concentrations of mitoxantrone (0.01–1.0 µM) were added to the wells and incubated for 72 h. At the end of the treatment, 10 µM of CCK8 solution was added to each well for 1 h culture at 37°C. Absorbance was measured with a spectrophotometer (Thermo Scientific Evolution 600, China) at a wavelength of 450 nm and compared with 630 nm.

Apoptosis assessment
After a 48-h culture, at least 1×10⁷ untreated and mitoxantrone-treated cells were collected and washed twice with cold PBS, stained with 5 µl of Annexin V-FITC and 5 µl of propidium iodide (PI) for 15 min, and subjected to flow cytometry (Becton Dickinson, CA, USA) to analyze apoptosis.

Lentiviral infection of cell lines
The lentiviral constructs PsPAX2, VSVG, pSIN4-EF2-ABCG2-IRE5-Neo (from Dr. Ren-He Xu’s laboratory) and pSIN4-EF2-EGFP-IRE5-Neo plasmids (from Dr. James Thomson’s laboratory) were used to make viral stocks by transfection of 293FT cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), as previously described. The lentiviral supernatants were harvested 72 h post-transfection and were filtered (0.45 µm) prior to infection of the cell lines. After a 48-h infection (MOI: 5–50), the K562 cell lines were allowed to recover for 24 h in fresh media and were thereafter referred to K562/ABCG2 cells. The cells were then allowed to grow for 72 h before being subjected to additional assays.

Western blot analysis
Protein (50 µg/sample) was separated in 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred electrophoretically to polyvinylidene fluoride (PVDF) membranes. The membranes were saturated in PBS-T containing 5% nonfat milk (blocking buffer) overnight at 4°C with the primary antibodies. The dilutions of the antibodies used for western blotting were as follows: PI3K p85 (Tyr458)/p55 (Tyr199) 1:1000 (Cell Signaling Technology, Beverly, MA, USA), PI3K 1:1000 (Abcam, MO, USA), phosphorylated-Akt (p-Akt) (S473) 1:400 (Cell Signaling Technology, Beverly, MA, USA), PTEN 1:1000 (Abcam, MO, USA), and β-actin 1:1000 (Abcam, MO, USA). The membranes were then incubated for 60 min at room temperature with an HRP-linked secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein bands were visualized using the Chei DocTM MP imaging system (BioRad). The blots shown are representative of three different experiments.

RNA isolation, RT-PCR and real-time RT-PCR
Total RNA (2 µg) was reverse transcribed using the M-MLV First Strand Kit (Invitrogen, Carlsbad, CA, USA). The transcript levels for the genes of interest were normalized to the GAPDH transcripts. The gene-specific primers and RT-PCR conditions are summarized in Table 2. Real-time PCR was performed using a SYBR qPCR Mix (Toyobo, TOYOBO CO., LTD, JAPAN) on an ABI StepOnePlus (Applied Biosystems, Foster City, CA, USA) with the specific primers. The thermal cycler conditions were as follows: 95°C for 1 min, followed by 40 cycles of 95°C for 10 s, 61°C for 20 s, and 72°C for 30 s.

Cellular surface expression of ABCG2
For the phenotypic analysis of the cell lines, the cells were washed in PBS and then stained for 30 min at room temperature with a PE anti-human CD338 antibody (ABCG2, 1:100, Biolegend, San Diego, CA, USA), and a PE-IgG2b isotype control (1:100, Biolegend, San Diego, CA, USA) used as a negative control. Finally, the cells were washed twice with ice-cold PBS and then analyzed by flow cytometry (Becton Dickinson, Mountain View, CA, USA).

Side population analysis
The cell suspensions were labeled with Hoechst 33342 (Invitrogen, Carlsbad, CA, USA) dye for side population analysis according to standard protocol [23]. Cells were briefly suspended in pre-warmed Hepes buffer containing 2% FBS at a density of 10⁶/ml. Hoechst 33342 dye (Invitrogen, Carlsbad, CA,
USA) was then added at a final concentration of 5 μg/ml (37°C for 90 min) in the presence or absence of verapamil (50 μM; Sigma) with intermittent shaking. The cells were counterstained created using GraphPad Prism 5 software.

Differences between the populations were calculated using Student’s t test or one-way ANOVA, as appropriate. The diagrams were statistical analysis

The comparisons of the chronic myeloid leukemia patients and normal donors or among the cell lines were made using the Statistical Package for the Social Sciences (SPSS) version 17.0. Differences were considered significant for P<0.05. The differences between the populations were calculated using Student’s t test or one-way ANOVA, as appropriate. The diagrams were created using GraphPad Prism 5 software.

Results

ABCG2 overexpression decreased drug sensitivity and drug-induced inhibition of DNA synthesis in leukemia cell lines

Cellular resistance to imatinib can arise through a variety of mechanisms, including mutations in the BCR-ABL kinase and increased efflux by multidrug resistance transporters such as P-glycoprotein (P-gp) and ABCG2 [24,25,26]. Imatinib stimulates ABCG2-specific ATPase activity and is both a substrate and an inhibitor of ABCG2 [13,27]. To determine whether ABCG2 is related to CML resistance, the K562, K562/ABCG2 (ABCG2 overexpressing), K562/AO2 (resistance to adriamycin) and K562/IMR (resistance to imatinib) cell lines were exposed to 10 nM, 100 nM or 1 μM of mitoxantrone. Compared with the wild-type K562 cells, increased mitoxantrone resistance was observed in K562/ABCG2, K562/AO2 and K562/IMR cells after 72-h treatment with 100 nM or 1 μM of mitoxantrone (P<0.05) (Fig. 1a and Table 3), with comparable mitoxantrone-induced apoptosis (P>0.05) (Fig. 1b). The results indicated that ABCG2 might attenuate the cytotoxic effects of mitoxantrone in CML.

Next, we evaluated the effect of ABCG2 overexpression on the mitoxantrone-induced cell cycle changes in leukemia cell lines. As shown in Fig. 1c and Fig. S4, after 72-h treatment with mitoxantrone, the proportion of K562, K562/ABCG2, and K562/AO2 cells in S phase was significantly decreased in concentration-dependent manner (P<0.05), indicating an inhibition in DNA synthesis by mitoxantrone. However, compared with wild-type K562 cells, the subpopulation in the S phase was remarkably higher in K562/ABCG2, K562/AO2 and K562/IMR cells when treated with 100 nM or 1 μM of mitoxantrone (P<0.05). These findings suggest that S-phase blockage might be an underlying mechanism contributing to drug resistance and the pivotal cross between drug resistance and tumor growth.

ABCG2 expression regulated the SP phenotype, and PTEN protein deletion increased p-Akt in resistant leukemia cells

As reported, PTEN deletion influences the disease progression of both CML and B-ALL by regulating its downstream target Akt1 [21], through which the BCR-ABL fusion gene regulates ABCG2 expression [28]. Thereby, we evaluated the endogenous levels of PTEN, PI3K, p-PI3K, p-Akt and ABCG2 in four leukemia cell lines. Compared with K562 cells, the expression level of PTEN protein was decreased significantly in all drug-resistant cells, with upregulated levels of BCR-ABL transcript detected by RT-PCR (Fig. 2a) (Tab. 2) and upregulated p-Akt protein detected by western blot (Fig. 2b). Additionally, ABCG2 mRNA levels (Fig. 2a) were significantly higher and the ABCG2+ population (Fig. 2c and d) was significantly larger in K562/ABCG2 and K562/IMR cells than in K562 and K562/AO2 cells. The siRNA-mediated knockdown of PTEN significantly increased ABCG2 transcript level in K562/ABCG2 cell (Fig. S3). These results suggested that the down-regulation of PTEN along with both p-Akt and ABCG2 upregulation might contribute to drug resistance in K562/ABCG2 and K562/IMR cells but not in K562/AO2 cells.

Because functional ABCG2 has been reported to be overexpressed on the surface of primary CML stem cells [29], we combined surface marker characteristics with Hoechst dye efflux to explore the interaction of the PI3K/Akt pathway, ABCG2 expression and the SP fraction specifically in the primitive stem cell subset. Flow cytometry confirmed higher fractions of SP cells in the K562/ABCG2 and K562/IMR cell lines compared with K562 and K562/AO2 cells (P<0.05) (Fig. 2e and Fig. S1). In addition, ABCG2 transcript levels were quantified by RT-PCR in Hoechst 33342-labeled sorted SP and non-SP fractions. Higher expression level of ABCG2 was present in the SP fraction compared to the non-SP fraction in K562/ABCG2 cell, whereas

| Gene     | Strand | Primer sequences | Annealing temperature |
|----------|--------|------------------|-----------------------|
| PTEN     | sense  | 5′- ACCAGGAGGACGAAAGACCT -3′ | 61.5°C |
|          | anti-sense | 5′- GCATTGCTGAGTACCAAA -3′ | |
| ABCG2    | sense  | 5′- ATTGAAGTCAGACCATGGGT -3′ | 61.0°C |
|          | anti-sense | 5′- TGATCTCAGAGGCAAGAGTT -3′ | |
| GAPDH    | sense  | 5′- AGGTGACACTATAGAATAAAGGTGAAGGTCGGAGTC -3′ | 68.0°C |
|          | anti-sense | 5′- GTACGACTCACTATAGGGAGACTCTCGCTCCTGGAAGATG -3′ | |
| BCR/ABL (b3a2) | sense | 5′- GCCATCCGTGCCATCCATA -3′ | 58.5°C |
|          | anti-sense | 5′- TCCAAGCGAGCGCTCTCATCA -3′ | |

Table 2. PCR primers and conditions.

doi:10.1371/journal.pone.0088298.t002
Figure 1. K562 cells with ABCG2 overexpression exhibited attenuated apoptosis and were no longer arrested in S phase by mitoxantone treatment. (a, b) After exposure to 10 nM, 100 nM or 1 μM of mitoxantone for 72 h, the cell lines were subjected to flow cytometry to quantify the number of apoptotic cells, and an increased drug resistance was observed in K562/ABCG2, K562/AO2 and K562/IMR cells compared with wild-type K562 cells. (c) The cell cycle phase was determined by flow cytometry after treatment with different concentrations of mitoxantone, which decreased the inhibition of DNA synthesis at S phase in K562/ABCG2, K562/AO2 and K562/IMR cells compared with wild-type K562 cells. The histogram represented the means ± s.d. for three replicates. *P<0.05.

doi:10.1371/journal.pone.0088298.g001

Table 3. The ratio of viable cells after 72-h treatment with mitoxantone at a range of concentrations in the presence of LY294002 or rapamycin by CKK8 assay.

| Mitoxantrone | K562         | K562/ABCG2   | K562/AO2     | K562/IMR     |
|--------------|--------------|--------------|--------------|--------------|
|              | +LY          | +LY          | +LY          | +LY          |
| 10 nM        | 0.90±        | 0.80±        | 0.91±        | 0.91±        |
|              | 0.04±        | 0.07±        | 0.04±        | 0.08±        |
| 100 nM       | 0.60±        | 0.48±        | 0.53±        | 0.82±        |
|              | 0.08±        | 0.07±        | 0.06±        | 0.04±        |
| 1 μM         | 0.39±        | 0.17±        | 0.23±        | 0.24±        |
|              | 0.05±        | 0.05±        | 0.08±        | 0.08±        |

Each value represents the mean value ± s.d. from three individual experiments. 
* Versus cells without LY294002 or rapamycin treatment within each cell group, P<0.05. 
# Versus K562 wild-type cells without LY294002 or rapamycin when treated with the same concentration of mitoxantrone, P<0.05. 
$ Versus K562/AO2 cells among all of the experimental cells treated with LY294002, P<0.05. 
& Versus K562/AO2 cells among all the experimented cells treated with rapamycin, P<0.05.

doi:10.1371/journal.pone.0088298.t003
Figure 2. Detection of the PTEN/PI3K/Akt signal pathway, ABCG2 and SP in leukemia cells. (a) BCR-ABL transcript expression was upregulated in all drug-resistant cells, whereas higher ABCG2 transcript was only detected in K562/ABCG2 and K562/IMR cells. (b) Western blot analysis revealed decreased PTEN protein but increased p-Akt expression in K562/ABCG2, K562/AO2 and K562/IMR cells. (c) Expression of CD338 (anti-ABCG2) on the cell surface were detected by FCM. IgG2b-PE was used as an isotype control. (d) The distribution of ABCG2+ cells was detected by flow cytometry (FCM). The histogram demonstrates a higher ratio of ABCG2+ cells in K562/ABCG2 and K562/IMR cell lines. The results were represented as the mean ± s.d. of three experiments. *P<0.05. (e) The increased SP fraction was observed in K562/ABCG2 and K562/IMR cells. Each sample was incubated with 50 μM verapamil as a control, and only PI-negative (live) cells were gated to be analyzed.
doi:10.1371/journal.pone.0088298.g002

Figure 3. PI3K/Akt pathway activation and the fraction of ABCG2+ and SP cells was detected by RT-PCR, western blotting and FACS analysis in leukemia cells before or after incubation with 20 μM LY294002 or 100 nM rapamycin for 72 h. (a, b) After LY294002 or rapamycin treatment, activation of the PTEN transcript and down-regulation of p-PI3K and p-Akt were detected in four cell lines. (c) A reduced fraction of ABCG2 cells in K562/ABCG2 and K562/IMR cells was observed after treatment. (d) The increased SP fraction was abolished by LY294002 or rapamycin treatment in K562/ABCG2 and K562/IMR cells. All results are presented as the means ± s.d. from three independent experiments. *P<0.05.
doi:10.1371/journal.pone.0088298.g003
no similar response was yielded in K562 cell (Fig. S2a–b) These findings further demonstrated that ABCG2 might contribute essentially to the SP phenotype.

PTEN regulated the ABCG2 + fraction, SP phenotype and drug sensitivity through the PI3K/Akt pathway in leukemia cells

To determine whether the PI3K/Akt pathway is involved in drug resistance through the regulation of ABCG2, leukemia cells were treated with the PI3K inhibitor LY294002 (20 μM) or the mTOR inhibitor rapamycin (100 nM) for 72 h. Although the mRNA levels of both ABCG2 and BCR-ABL did not significantly change (Fig. 3a), activation of PTEN transcript and the down-regulation of both p-PI3K and p-Akt (Fig. 3b), as well as a reduced proportion of ABCG2 + cells (Fig. 3c), were observed in treated K562/ABCG2 and K562/IMR cells, suggesting that PI3K and Akt activity might regulate ABCG2 expression. Furthermore, we observed that incubation with LY294002 or rapamycin decreased the fractions of SP cells in K562/ABCG2 and K562/IMR cells (P<0.05) (Fig. 3d and Fig. S1). Taken together, these results indicated that the PI3K/Akt pathway participated in regulating the SP fraction through ABCG2.

Furthermore, as shown in Table 3, CCK8 analysis demonstrated that the incubation of leukemia cells with LY294002 or rapamycin strongly increased the sensitivity of leukemia cells to 100 nM or 1 μM of mitoxantrone (P<0.05), suggesting that chemosensitivity to mitoxantrone is tightly correlated with decreased p-PI3K and p-Akt expression in the resistant K562 cells. When pretreated with either LY294002 or rapamycin, K562/ABCG2 and K562/IMR cells exhibited a more significant decrease in the proportion of viable cells after treatment with 100 nM or 1 μM mitoxantrone than did K562/AO2 cells (P<0.05). These data suggest that p-PI3K, p-Akt or ABCG2 activity may fractionally participate in chemoresistance in K562/AO2 cells.

No substantial difference in the ABCG2 + fraction but an increased SP fraction in CML patients in AP/BP compared with the control group

Based on the results of CML cell lines, the endogenous mRNA and protein levels of ABCG2 in 61 consecutive CML patients with

Figure 4. Endogenous expression of ABCG2 and SP fractions in CML patients. (a) The ABCG2 transcript in CML patients was determined by real-time RT-PCR using the RQ values with GAPDH mRNA as the endogenous control. In contrast to normal donors, no substantial difference in the ABCG2 transcript levels was detected in CML patients. *P<0.05. (b) ABCG2+ cells were labeled by CD338-PE and detected by FACS, using IgG2b-PE as the isotype control. There were no significant differences among the groups. *P<0.05. (c) Significantly higher percentages of SP cells were observed in CML blasts at AP/BP using flow cytometry. *P<0.05.
doi:10.1371/journal.pone.0088298.g004
Ph-positive metaphases and/or BCR-ABL–positive transcripts in the CP (chronic phase) and in 35 patients in AP/BP (accelerated phase/blastic phase) were detected by real-time RT-PCR and FACS analysis, respectively, at our hospital (Tab. 1). ABCG2+ cells and the mRNA levels in CML patients in different phases exhibited no substantial differences (P > 0.05) but were obviously higher than in normal donors (Fig. 4a–b).

Stem cells are frequently identified as the “side population” by flow cytometry based on ABCG2-mediated efflux of Hoechst 33342 dye. Incubation of the leukemia cells with 50 μM verapamil, known to block ABC transporter activity, abolished part of the SP as a negative control. ABCG2 transcript differed significantly between SP and non-SP cells in some CML patient (Fig. S2c–d). Flow cytometry revealed a very small SP fraction, ranging from 0.11% to 1.14% in the cases, and a significantly higher percentage of the SP cells in CML patients at AP/BP compared with the healthy donors (P < 0.05) (Fig. 4c). Our data suggest that an increase in the SP fraction might confer a survival advantage to CML cells.

The SP phenotype was correlated with low PTEN and high p-Akt levels in CML patients. PTEN maintains normal hematopoietic stem cells and prevents leukemia development from leukemia stem cells [30,31]. To determine whether increased ratios of the SP would be related to the down-regulation of PTEN, both transcript and protein levels of PTEN were detected in CML patients. In leukemia blasts, the levels of PTEN transcript were surprisingly increased compared to the normal donors (P > 0.05) (Fig. 5a). However, PTEN protein was remarkably decreased in CML patients in AP/BP compared with other patients (P < 0.05), suggesting that low PTEN protein accompanying the SP phenotype was limited to the status of the disease. Furthermore, p-Akt was activated in some CML samples with low expression of PTEN protein (P < 0.05) (Fig. 5b–d). Our study further demonstrated that the SP fraction may contribute to the progression of CML, as indicated by decreased PTEN protein expression and Akt activation.

Discussion

In light of the crucial role of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia, TKIs have become the first-line therapy for most patients with chronic myelogenous leukemia [4,32,33]. However, TKIs do not kill CML stem cells [34]. Although more than 80% of CML patients in chronic phase can achieve an ongoing complete hematologic response after treatment with imatinib, a considerable number of cases eventually
progress to the accelerated phase and even blast crisis [35,36]. Additionally, BCR-ABL-positive malignant cell clones have been shown to persist within the CD34+ stem cell fractions, even in CML patients for whom imatinib had induced a complete cytogenetic remission [37]. Given that CML patients harbor quiescent CML stem cells that may serve as reservoir for disease progression to blast crisis, there is a strong possibility of the existence of imatinib-refractory CML stem cells.

The drug pump ABCG2 is a multidrug resistance protein and is well known as a specific phenotype of the SP cells with stem-like properties [15]. Consistent with previous reports that imatinib is an inhibitor and substrate for ABCG2 [13,27,28], we observed upregulation of ABCG2 in K562/IMR cells and K562/ABCG2 cells, both of which accordingly exhibited higher ratios of SP cells and decreased susceptibility to mitoxantrone due to higher levels of ABCG2. Furthermore, PTEN was revealed to be involved in ABCG2-mediated multi-drug resistance for CML through the PI3K/Akt signaling pathway in our study. Lower PTEN expression was observed in drug-resistant CML cells; consistent with our reports in human embryonic stem cells, the overexpression of ABCG2 in H9 cells leads to p-Akt activation [38]. Higher p-Akt expression levels were also detected in both K562/ABCG2 and K562/IMR cells. Second, consistent with previous studies in human glioma, primary esophageal carcinoma and epithelial carcinoma cells [22,39,40], our data demonstrated increased drug sensitivity, down-regulation of p-PI3K and p-Akt, suppression of the ABCG2 and a decrease in the SP fraction in K562/ABCG2 and K562/IMR cells after LY294002 or rapamycin treatment. These findings suggest that the chemotherapeutic sensitivity and the fractions of ABCG2 and SP cells in drug-resistant CML might be mediated by the PI3K/Akt signaling pathway, which is consistent with our previous reports in acute leukemia [41]. Therefore, accumulating data provide underlying connections among the PTEN, PI3K/Akt pathway, multidrug resistance transporters, stem-like character, and therapeutic resistance, suggesting that activation of this pathway also enhances the ability of CML cancer stem-like cells to expel drugs.

This study further focused on the complex interaction between PTEN and ABCG2 in CML cases to explore whether such regulation existed in the clinic process. Inconsistent with data from CML cell lines, no substantial differences in the ABCG2+ phenotype and ABCG2 mRNA levels were detected among different stages of CML blasts and normal cells. Additionally, the research in glioma tumor reported that PI3K inhibitor treatment changed the activity of ABCG2 in neurospheres, but the expression levels of the mRNA and protein were unaffected [22]. These data indicate that ABCG2 function, rather than its mRNA or protein expression, might play a more important role in initiation and progress of CML. SP cells are also found in a variety of mammalian species, including humans, where their frequency is low [42]. Inconsistent with ABCG2 expression, a higher percentage of SP compared with the donors was observed in the AP/BB group, which partly suggested that monitoring the SP ratio could predict disease progression and might be an optimal indicator to represent in vivo ABCG2 function. Meanwhile, similar to the results from CML cell lines, this study also demonstrated that absent/low expression of PTEN at the protein level and subsequent p-Akt activation in the CML groups might promote the acceleration of CML development and an increased SP ratio. Nevertheless, more efforts are needed to reveal the precise mechanism of how loss of the tumor suppressor PTEN regulates ABCG2 function and further enhances the SP phenotype through the PI3K/Akt pathway in CML.

In summary, to investigate the perplexing relationships among PTEN, ABCG2 and the SP in CML, our studies demonstrated that PTEN played an essential role in regulating the SP in CML through the PI3K/Akt signaling pathway in vitro. Then, our study revealed that the SP phenotype and ABCG2 function rather than ABCG2 expression was correlated with drug resistance and disease progression in CML patients, which was mediated at least partially by p-Akt activation. Therefore, intervention in the functional enhancement of p-Akt mediated by the loss of PTEN inhibition would provide a potential therapeutic strategy for targeting CML stem cells.

Supporting Information

Figure S1 The distribution of the SP phenotype was assessed by flow cytometry in cell lines before and after treatment with LY294002 or rapamycin. Each sample was incubated with 50 μM verapamil as a control, and only PI-negative (live) cells were gated to be analyzed. The ABCG2+ population was significantly larger in K562/ABCG2 and K562/IMR cells than in the other cell types. (TIF)

Figure S2 ABCG2 transcript in the SP fraction. ABCG2 mRNA was analyzed by RT-PCR in the flow cytometry-selected SP fraction and compared with the non-SP fraction in K562 cells (a), K562/ABCG2 cells (b), CML-CP patient No. 23 (c) and CML-AP/BP patient No. 9 (d). GAPDH was used as a control. (TIF)

Figure S3 siRNA directed against PTEN specifically inhibited PTEN expression in leukemia cell lines. One hundred nanomolar siRNA directed against PTEN specifically inhibited PTEN expression in the K562/ABCG2 cell line. RT-PCR was performed 48 h after the leukemia cells were treated with PTEN siRNA or control siRNA to evaluate PTEN and ABCG2 expression. (TIF)

Figure S4 K562 cells overexpressing ABCG2 overcame mitoxantrone-induced S-phase arrest. (a, b) After exposed to 10 nM, 100 nM or 1 μM of mitoxantrone for 72 h, the cell lines were subjected to flow cytometry to determine the cell cycle distribution, and a decreased the inhibition of DNA synthesis at S phase was observed in the K562/ABCG2, K562/AO2 and K562/IMR cells compared with the wild-type K562 cells. The histogram represented the means ± s.d. for three replicate determinations. *P<0.05. (TIF)

Acknowledgments

We thank Dr. James Thomson for the pSIN4-EF2-EGFP-IRES-Neo lentiviral plasmid, Dr. Ren-He Xu for the pSIN4-EF2-ABCG2-IRES-Neo lentiviral plasmid, Hui-En Zhan and Yan-Hong Zhou for technical assistance, and Dr. Bei Liu, Zheng Zhang and Xiao-Ping Chen for their critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: HZ FPC. Performed the experiments: FFH LZ. Analyzed the data: FFH LZ HZ. Contributed reagents/materials/analysis tools: DSW YHY XYY XLZ. Wrote the paper: FFH LZ HZ. Obtained permission for use of cell line: DSW. Provided the experiment station: FPC HZ.
References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 252–294.
2. Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85-109.
3. Rowley JD (1975) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293.
4. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082.
5. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640–2653.
6. Kantarjian HM, Giles F, Gattermann N, Bhailla K, Alimena G, et al. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110: 3340–3346.
7. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guillot F, et al. (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309–2315.
8. Cortes J, Talpaz M, O’Brien S, Jones D, Luthra R, et al. (2003) Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 11: 3425–3432.
9. Albano F, Anelli L, Zagaria A, Coccaro N, D’Addabbo P, et al. (2010) Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia. Oncogene 29: 2309–2516.
10. Barnes DJ, Schuhleins B, Adeqogu S, Melo JV (2003) Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24: 6432–6440.
11. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, et al. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood. 97: 720–728.
12. Thomas J, Wang L, Clark RE, Pirmahamad M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 104: 3739–3745.
13. Burger H, van Tol H, Boersma AW, Boersma EW, Alcorn MJ, et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 104: 2940–2942.
14. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15663–15670.
15. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028–1034.
16. Ross DD, Nakanishi T (2010) Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol 596: 251–290.
17. Doyle L, Ross DD (2005) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340–7358.
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.
19. Pei J, Zheng T, Tribule DJ, Mitch DG, Gervell DJ, et al. (1993) Allergic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 53: 1922–1926.
20. Gronbaek K, Zeuthen J, Guldborg P, Ralfkiaer E, Hou-Jensen K (1998) Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood 91: 4388–4390.
21. Peng C, Chen Y, Yang Z, Zhang H, Osterby L, et al. (2010) PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemia in mice. Blood 115: 626–635.
22. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, et al. (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226–233.
23. Goodell MA (2003) Stem cell identification and sorting using the Hoechst 33342 side population (SP). Curr Protoc Cytom Chapter 9: Unit9 18.
24. Weidberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 6: 231–238.
25. Illner T, Schach M, Platzbecker U, Freiberg-Richter J, Oeschlagel U, et al. (2004) Polyglycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18: 401–408.
26. Ozegvy-Laczka C, Hegedu T, Varzad Y, Ujelly O, Schuett J, et al. (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 63: 1485–1495.
27. Houghton PJ, Germain GS, Harwood FC, Schuett J, Stewart CF, et al. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333–2337.
28. Nakanishi T, Shiozawa K, Hassel BA, Ross DD (2006) Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells. BCRP-mediated resistance to imatinib is attenuated by imatinib-reduced expression of BCRP. Blood 108: 678–684.
29. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 108: 1370–1373.
30. Zhang J, Gründley JC, Yin T, Jayainghe S, He XG, et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441: 518–522.
31. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475–482.
32. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830.
33. Kantarjian H, Giles F, Wunderle L, Bhailla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542–2551.
34. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziereni S, et al. (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23: 1999–2006.
35. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Rouse SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042.
36. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2209–2205.
37. Bharia R, Holz M, Niu N, Gray R, Snyder DS, et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101: 4701–4707.
38. Zeng H, Park JW, Guo M, Lin G, Grassall D, et al. (2009) Lack of ABCG2 expression and side population properties in human pluripotent stem cells. Stem Cells 27: 2435–2445.
39. Li H, Guo Q, Guo L, Lu SH (2011) The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 11: 930–950.
40. Hegedu C, Tura-Feles K, Antalffy G, Brozik A, Kasza I, et al. (2012) PI3-K/AKT pathway in acute myeloid leukemia. Oncogene 29: 2509–2516.
41. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, et al. (1997) Pgp efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3: 1337–1345.